Company profile RIGL
After 38 days of this quarter the interest is at 7.0. Based on that we can calculate that during remaining 53 days it will total up to 17.0. Rigel Pharmaceuticals expected interest is significantly lower compared to previous quarter (-45.2%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 24 | 20 -16.7% QoQ | 24 20.0% QoQ | 27 12.5% QoQ |
| 2020 | 43 79.2% YoY 59.3% QoQ | 40 100.0% YoY -7.0% QoQ | 208 766.7% YoY 420.0% QoQ | 53 96.3% YoY -74.5% QoQ |
| 2021 | 86 100.0% YoY 62.3% QoQ | 50 25.0% YoY -41.9% QoQ | 28 -86.5% YoY -44.0% QoQ | 33 -37.7% YoY 17.9% QoQ |
| 2022 | 30 -65.1% YoY -9.1% QoQ | 27 -46.0% YoY -10.0% QoQ | 13 -53.6% YoY -51.9% QoQ | 22 -33.3% YoY 69.2% QoQ |
| 2023 | 27 -10.0% YoY 22.7% QoQ | 24 -11.1% YoY -11.1% QoQ | 20 53.8% YoY -16.7% QoQ | 31 40.9% YoY 55.0% QoQ |
| 2024 | 7 -74.1% YoY -77.4% QoQ | - | - | - |
The average 5 years interest of Rigel Pharmaceuticals was 3.22 per week. The last year interest of Rigel Pharmaceuticals compared to the last 5 years has changed by -41.61%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -18.61%.
There is not enough data for Rigel Pharmaceuticals products to provide analysis
There is not enough data for Rigel Pharmaceuticals products to provide correlation calculation
There is not enough data for Rigel Pharmaceuticals products to provide analysis
Google Trends for Tavalisse
Q4 -22.8% YoY, +7.7% QoQ | Q1 -53.7% YoY, -30.6% QoQ | Correlation: 0.01
After 38 days of this quarter the interest is at 57.0. Based on that we can calculate that during remaining 53 days it will total up to 136.0. Tavalisse expected interest is significantly lower compared to same quarter last year (-53.7%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 158 | 306 93.7% QoQ | 388 26.8% QoQ | 193 -50.3% QoQ |
| 2020 | 242 53.2% YoY 25.4% QoQ | 301 -1.6% YoY 24.4% QoQ | 297 -23.5% YoY -1.3% QoQ | 326 68.9% YoY 9.8% QoQ |
| 2021 | 263 8.7% YoY -19.3% QoQ | 112 -62.8% YoY -57.4% QoQ | 224 -24.6% YoY 100.0% QoQ | 136 -58.3% YoY -39.3% QoQ |
| 2022 | 267 1.5% YoY 96.3% QoQ | 297 165.2% YoY 11.2% QoQ | 217 -3.1% YoY -26.9% QoQ | 254 86.8% YoY 17.1% QoQ |
| 2023 | 294 10.1% YoY 15.7% QoQ | 230 -22.6% YoY -21.8% QoQ | 182 -16.1% YoY -20.9% QoQ | 196 -22.8% YoY 7.7% QoQ |
| 2024 | 57 -80.6% YoY -70.9% QoQ | - | - | - |
The average 5 years interest of Tavalisse was 19.0 per week. The last year interest of Tavalisse compared to the last 5 years has changed by -8.32%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -23.29%.
After 38 days of this quarter the interest is at 57.0. Based on that we can calculate that during remaining 53 days it will total up to 136.0. Rezlidhia expected interest is significantly lower compared to same quarter last year (-52.6%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 36 | 26 -27.8% QoQ | 218 738.5% QoQ | 50 -77.1% QoQ |
| 2020 | 114 216.7% YoY 128.0% QoQ | 142 446.2% YoY 24.6% QoQ | 50 -77.1% YoY -64.8% QoQ | 41 -18.0% YoY -18.0% QoQ |
| 2021 | 81 -28.9% YoY 97.6% QoQ | 27 -81.0% YoY -66.7% QoQ | 86 72.0% YoY 218.5% QoQ | 273 565.9% YoY 217.4% QoQ |
| 2022 | 46 -43.2% YoY -83.2% QoQ | 151 459.3% YoY 228.3% QoQ | 142 65.1% YoY -6.0% QoQ | 164 -39.9% YoY 15.5% QoQ |
| 2023 | 287 523.9% YoY 75.0% QoQ | 118 -21.9% YoY -58.9% QoQ | 92 -35.2% YoY -22.0% QoQ | 164 0.0% YoY 78.3% QoQ |
| 2024 | 57 -80.1% YoY -65.2% QoQ | - | - | - |
The average 5 years interest of Rezlidhia was 9.1 per week. The last year interest of Rezlidhia compared to the last 5 years has changed by 6.26%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 52.28%.
After 38 days of this quarter the interest is at 44.0. Based on that we can calculate that during remaining 53 days it will total up to 105.0. Fostamatinib expected interest is significantly lower compared to previous quarter (-58.5%) and same quarter last year (-50.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 103 | 267 159.2% QoQ | 111 -58.4% QoQ | 256 130.6% QoQ |
| 2020 | 56 -45.6% YoY -78.1% QoQ | 82 -69.3% YoY 46.4% QoQ | 252 127.0% YoY 207.3% QoQ | 207 -19.1% YoY -17.9% QoQ |
| 2021 | 156 178.6% YoY -24.6% QoQ | 288 251.2% YoY 84.6% QoQ | 247 -2.0% YoY -14.2% QoQ | 160 -22.7% YoY -35.2% QoQ |
| 2022 | 249 59.6% YoY 55.6% QoQ | 284 -1.4% YoY 14.1% QoQ | 181 -26.7% YoY -36.3% QoQ | 168 5.0% YoY -7.2% QoQ |
| 2023 | 211 -15.3% YoY 25.6% QoQ | 76 -73.2% YoY -64.0% QoQ | 212 17.1% YoY 178.9% QoQ | 253 50.6% YoY 19.3% QoQ |
| 2024 | 44 -79.1% YoY -82.6% QoQ | - | - | - |
The average 5 years interest of Fostamatinib was 14.86 per week. The last year interest of Fostamatinib compared to the last 5 years has changed by -8.28%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -9.37%.
There is not enough data for warm autoimmune hemolytic anemia treatment to provide analysis
There is not enough data for warm autoimmune hemolytic anemia treatment to provide correlation calculation
There is not enough data for warm autoimmune hemolytic anemia treatment to provide analysis
After 39 days of this quarter the interest is at 22.0. Based on that we can calculate that during remaining 52 days it will total up to 51.0. COVID-19 treatment expected interest is significantly lower compared to same quarter last year (-48.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 3 | 8 166.7% QoQ | 3 -62.5% QoQ | 3 0.0% QoQ |
| 2020 | 355 11733.3% YoY 11733.3% QoQ | 594 7325.0% YoY 67.3% QoQ | 467 15466.7% YoY -21.4% QoQ | 343 11333.3% YoY -26.6% QoQ |
| 2021 | 287 -19.2% YoY -16.3% QoQ | 196 -67.0% YoY -31.7% QoQ | 409 -12.4% YoY 108.7% QoQ | 307 -10.5% YoY -24.9% QoQ |
| 2022 | 259 -9.8% YoY -15.6% QoQ | 174 -11.2% YoY -32.8% QoQ | 170 -58.4% YoY -2.3% QoQ | 118 -61.6% YoY -30.6% QoQ |
| 2023 | 99 -61.8% YoY -16.1% QoQ | 61 -64.9% YoY -38.4% QoQ | 53 -68.8% YoY -13.1% QoQ | 69 -41.5% YoY 30.2% QoQ |
| 2024 | 22 -77.8% YoY -68.1% QoQ | - | - | - |
The average 5 years interest of COVID-19 treatment was 15.33 per week. The last year interest of COVID-19 treatment compared to the last 5 years has changed by -68.49%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 1205.41%.
There is not enough data for interleukin receptor-associated kinase inhibitor program to provide analysis
There is not enough data for interleukin receptor-associated kinase inhibitor program to provide correlation calculation
There is not enough data for interleukin receptor-associated kinase inhibitor program to provide analysis
There is not enough data for receptor-interacting serine/threonine-protein kinase inhibitor program to provide analysis
There is not enough data for receptor-interacting serine/threonine-protein kinase inhibitor program to provide correlation calculation
There is not enough data for receptor-interacting serine/threonine-protein kinase inhibitor program to provide analysis
There is not enough data for Rigel Pharmaceuticals careers to provide analysis
There is not enough data for Rigel Pharmaceuticals careers to provide correlation calculation
There is not enough data for Rigel Pharmaceuticals careers to provide analysis